HC Wainwright & Co. Maintains Buy on Ionis Pharmaceuticals, Lowers Price Target to $70
Benzinga Newsdesk 6 hours ago
Analyst RatingsNewsPrice Target
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy and lowers the price target from $100 to $70.
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy and lowers the price target from $100 to $70.